Fig. 4.
Fig. 4. Associations between FFS and staining intensity of BCL-2 expression in HRS cells for patients of all stages treated with ABVD or equivalent regimens. / (A) All patients. (B) patients with Ann Arbor stage III or IV. ○ indicates strong BCL-2 expression; ■, weak BCL-2 expression; ⋄, no BCL-2 expression.

Associations between FFS and staining intensity of BCL-2 expression in HRS cells for patients of all stages treated with ABVD or equivalent regimens.

(A) All patients. (B) patients with Ann Arbor stage III or IV. ○ indicates strong BCL-2 expression; ■, weak BCL-2 expression; ⋄, no BCL-2 expression.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal